Radioiodine treatment has been suggested as a potential treatment for breast cancer patients. Although the sodium iodide symporter (NIS) is not expressed in normal breast tissue, it is expressed in 70 -80% of breast cancers. However as in many differentiated thyroid cancers, 131 I uptake in breast cancer is limited due to the low levels of NIS located at the plasma membrane (1) .
Previous studies in thyroid cells have shown that pituitary tumor-transforming gene (PTTG) binding factor (PBF), is capable of altering the subcellular localisation of NIS and sequestering it in cytoplasmic vesicles (2) . This interaction can be abrogated by inhibiting the phosphorylation of PBF at tyrosine residue 174 using the Src inhibitor PP1. Mutants of PBF without this key residue are also unable to bind and sequester NIS (3) .
With PBF being upregulated in both thyroid and breast cancer (4) , we hypothesised that the interaction between NIS and PBF may also be apparent in breast cancer and that use of PP1 in breast cancer cells may increase radioiodine uptake. (Fig. 1A) . Similar reduction was also observed in MDA-MB-231 cells (30% reduction, p=0.002) (Fig. 1A) . As demonstrated previously all trans retinoic acid (ATRA) and dexamethasone increased NIS expression and radioiodine uptake in MCF-7 cells (5) (Fig. 1C) . This effect was significantly reduced when ATRA/dexamethasone treated cells were also transfected with PBF (22% reduction, p=0.03) (Fig. 1C) . MCF-7 cells transfected with NIS and PBF were treated with the Src inhibitor PP1, and their ability to uptake iodine assessed. In vehicle only treated cells there was a reduction in radioiodine uptake between NIS and NIS + PBF transfected cells (25% reduction, p=0.008) (Fig.  3A) . Cells transfected with NIS + PBF and treated with PP1 displayed increased uptake compared to control treated cells (24% increase, p=0.011) (Fig. 3A) . This was also observed in MDA-MB-231 cells with an initial reduction of 33% with PBF co-transfection (p=0.003) which was restored after treatment with PP1 (p=0.0008) (Fig. 3B) . In ATRA/dexamethasone treated cells, PBF transfection reduced radioiodine by 22% (p=0.03), and PP1 treatment increased radioiodine uptake by 43% (p=0.03) (Fig. 3C) . 
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MDA-MB-231 cells transfected with NIS-MYC (green)
and PBF-HA (red) were treated with the Src inhibitor PP1, and localisation of the two proteins visualised (Fig. 2 ). Cells treated with the vehicle control DMSO displayed co-localisation (yellow) of PBF and NIS in intracellular vesicles with some plasma membrane NIS evident. Cells treated with PP1 displayed less colocalisation between NIS and PBF, with a noticeable increase in NIS at the plasma membrane. 
